Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unihart CorpfiledCriticalUnihart Corp
Priority to BR9916771-9ApriorityCriticalpatent/BR9916771A/en
Publication of BR9916771ApublicationCriticalpatent/BR9916771A/en
Patente de Invenção: "COMPOSIçãO TLP IMUNOGêNICA". Apresente invenção refere-se a uma composição imunogênica,compreendendo pelo menos uma proteína de TLP ou umfragmento dela, e em particular, às composições nas quais osreferidos fragmentos podem compreender pelo menos um dospeptídeos reivindicados como Seq. ID N1, Seq. ID N2 e Seq. IDN3 no Pedido de Patente Europeu n<0> 93916141.0, ou opeptídeo reivindicado como seq. ID N1 no Pedido de PatenteItaliano n<0> RM96A000496, apropriado na terapia contradoenças tumorais e, em particular, contra NSCLC e câncerurogenital.Invention Patent: "TLP IMMUNOGENIC COMPOSITION". The present invention relates to an immunogenic composition, comprising at least one TLP protein or a fragment thereof, and in particular, to compositions in which said fragments may comprise at least one of the peptides claimed as Seq. ID N1, Seq. ID N2 and Seq. IDN3 in European Patent Application No. 93916141.0, or opeptide claimed as seq. ID N1 in Italian Patent Application n <0> RM96A000496, suitable for therapy against tumor diseases and, in particular, against NSCLC and cancer cells.
Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component.
Antibody, pharmaceutical composition, and uses of an effective amount of an agent, a therapeutically effective amount of an il-22 antibody, an immunogenic amount of antigen, and an immunogenicity enhancing amount of il-22 in combination, a effective amount of the antibody or fragment thereof and a sufficient amount of antibody or antigen-linked fragment thereof